Financial news, mergers and acquisitions, partnerships, and alliances.
HalioDx said that Chinese oncologists will gain access to its Immunoscore assay for predicting the risk of recurrence of early-stage colon cancer.
Industry executives said that clinical needs associated with antimicrobial resistance and sepsis are generating more interest in AST technologies.
BrightEdge was founded by the American Cancer Society to invest in for-profit companies developing novel cancer therapeutics and diagnostics.
The Life Sciences business grew 10 percent year over year, while the Diagnostics business inched up 1 percent.
The firm is selling more than 5.2 million shares at an offering price of $19 per share.